Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR2 - TNS1 |
Therapy | Buparlisib |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 - TNS1 | triple-receptor negative breast cancer | no benefit | Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated stable disease upon treatment with Buparlisib (BKM120), but also exhibited general toxicity (PMID: 29203461). | 29203461 |
PubMed Id | Reference Title | Details |
---|---|---|
(29203461) | Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. | Full reference... |